It analyzes pathway-level variants (GLP1R (rs6923761), GIPR (rs1800437), FTO (rs9939609), and MC4R (rs17782313)) that relate to the biology involved, offering context for a conversation with your provider rather than a prediction
Type 2 diabetes in adults: management (NG28)
Originally designed as a treatment for diabetes, GLP-1 medications help regulate blood sugar and insulin production
Remarkably, half of the participants managed to shed 15% of their body weight, and nearly one-third lost 20%
Beyond weight loss, GLP-1 agonists have demonstrated the ability to reduce major cardiovascular events, combat fatty liver disease, and alleviate obesity-related complications such as knee pain, sleep apnea, and acid reflux
No significant changes in other weight-related biochemical markers were observed